Cargando…

Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer's disease pathology and neurodegeneration along the Alzheimer's disease continuum

INTRODUCTION: White matter (WM) degeneration is a critical component of early Alzheimer's disease (AD) pathophysiology. Diffusion‐weighted imaging (DWI) models, including diffusion tensor imaging (DTI), neurite orientation dispersion and density imaging (NODDI), and mean apparent propagator MRI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moody, Jason F., Dean, Douglas C., Kecskemeti, Steve R., Blennow, Kaj, Zetterberg, Henrik, Kollmorgen, Gwendlyn, Suridjan, Ivonne, Wild, Norbert, Carlsson, Cynthia M., Johnson, Sterling C., Alexander, Andrew L., Bendlin, Barbara B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720004/ https://www.ncbi.nlm.nih.gov/pubmed/36479018 http://dx.doi.org/10.1002/dad2.12381

Ejemplares similares

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
por: Dong, Ruocheng, et al.
Publicado: (2023)

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
por: Salvadó, Gemma, et al.
Publicado: (2022)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status
por: Gallagher, Rigina L., et al.
Publicado: (2023)

Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum
por: Allison, Samantha L., et al.
Publicado: (2019)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum
por: Salvadó, Gemma, et al.
Publicado: (2022)

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
por: Benedet, Andréa L., et al.
Publicado: (2021)

Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non‐demented adults
por: Ennis, Gilda E., et al.
Publicado: (2021)

Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2022)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Gut inflammation associated with age and Alzheimer’s disease pathology: a human cohort study
por: Heston, Margo B., et al.
Publicado: (2023)

Impact of asthma on the brain: evidence from diffusion MRI, CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2023)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit
por: Johnson, Sterling C., et al.
Publicado: (2023)

Microstructural Neurodegeneration of the Entorhinal-Hippocampus Pathway along the Alzheimer’s Disease Continuum
por: Uchida, Yuto, et al.
Publicado: (2023)

Effect of Pathway-specific Polygenic Risk Scores for Alzheimer’s Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals
por: Xu, Yuexuan, et al.
Publicado: (2023)

Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum
por: Vilor-Tejedor, Natalia, et al.
Publicado: (2021)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Gut microbiome alterations in Alzheimer’s disease
por: Vogt, Nicholas M., et al.
Publicado: (2017)

Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration stratified by sex
por: Cumplido-Mayoral, Irene, et al.
Publicado: (2023)

Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels
por: Brugulat-Serrat, Anna, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease
por: Miners, James, et al.
Publicado: (2023)

The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease
por: Vogt, Nicholas M., et al.
Publicado: (2018)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study
por: Rodríguez-Fernández, Blanca, et al.
Publicado: (2022)

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
por: Grau-Rivera, Oriol, et al.
Publicado: (2021)

Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Lopez-Font, Inmaculada, et al.
Publicado: (2022)

Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults
por: Akinci, Muge, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gcf5kgfgm6v4uhcdrliai0rfqs